Guardant Health Inc logo

GH - Guardant Health Inc Share Price

$135.39 0.8  0.6%

Last Trade - 07/05/21

Large Cap
Market Cap £9.80bn
Enterprise Value £9.13bn
Revenue £205.2m
Position in Universe 790th / 6858
Unlock GH Revenue
Relative Strength (%)
1m -16.5%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -25.2%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.000 25.2 49.8 90.6 214.4 286.7 367.3 509.8 +83.6%
Balance Sheet
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020, GuardantHealth Inc revenues increased 34% to $286.7M. Net lossincreased from $75.7M to $253.8M. Revenues reflect UnitedStates segment increase of 36% to $264.7M, Internationalsegment increase of 10% to $22.1M. Higher net loss reflectsStock-based Compensation in increase from $5.5M to $123M(expense), Research and development expense increase of 74%to $139.8M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for GH
Graphical History


GH Revenue Unlock GH Revenue

Net Income

GH Net Income Unlock GH Revenue

Normalised EPS

GH Normalised EPS Unlock GH Revenue

PE Ratio Range

GH PE Ratio Range Unlock GH Revenue

Dividend Yield Range

GH Dividend Yield Range Unlock GH Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
GH EPS Forecasts Unlock GH Revenue
Profile Summary

Guardant Health, Inc. is a precision oncology company. The Company is focused on helping conquer cancer through use of its blood tests, data sets and analytics. It provides Guardant Health Oncology Platform. It provides liquid biopsy tests, such as Guardant360 and GuardantOMNI, for advanced stage cancer. Its liquid biopsy tests fuels its programs developing tests for recurrence and early detection, LUNAR-1 and LUNAR-2. Guardant360 is a molecular diagnostic test that measures 73 cancer-related genes from circulating tumor deoxyribonucleic acid (ctDNA). Its Guardant360 process includes blood collection, laboratory processing, analysis and reporting. Guardant360 is used for a range of applications, including translational science research and identifying target patient populations, drug development and commercialization post-drug approval.

Last Annual December 31st, 2020
Last Interim December 31st, 2020
Incorporated December 9, 2011
Public Since October 4, 2018
No. of Shareholders: 40
No. of Employees: 864
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 101,117,510
Free Float (0.0%)
Eligible for
GH Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for GH
Upcoming Events for GH
Wednesday 12th May, 2021
Guardant Health Inc at Bank of America Global Research Healthcare Conference (Virtual)
Friday 11th June, 2021 Estimate
Guardant Health Inc Annual Shareholders Meeting
Wednesday 16th June, 2021
Guardant Health Inc Annual Shareholders Meeting
Wednesday 4th August, 2021 Estimate
Q2 2021 Guardant Health Inc Earnings Release
Wednesday 3rd November, 2021 Estimate
Q3 2021 Guardant Health Inc Earnings Release
Frequently Asked Questions for Guardant Health Inc
What is the Guardant Health Inc share price?

As of 07/05/21, shares in Guardant Health Inc are trading at $135.39, giving the company a market capitalisation of £9.80bn. This share price information is delayed by 15 minutes.

How has the Guardant Health Inc share price performed this year?

Shares in Guardant Health Inc are currently trading at $135.39 and the price has moved by 61.27% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Guardant Health Inc price has moved by 12.46% over the past year.

What are the analyst and broker recommendations for Guardant Health Inc?

Of the analysts with advisory recommendations for Guardant Health Inc, there are there are currently 8 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Guardant Health Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Guardant Health Inc next release its financial results?

Guardant Health Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Guardant Health Inc dividend yield?

Guardant Health Inc does not currently pay a dividend.

Does Guardant Health Inc pay a dividend?

Guardant Health Inc does not currently pay a dividend.

When does Guardant Health Inc next pay dividends?

Guardant Health Inc does not currently pay a dividend.

How do I buy Guardant Health Inc shares?

To buy shares in Guardant Health Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Guardant Health Inc?

Shares in Guardant Health Inc are currently trading at $135.39, giving the company a market capitalisation of £9.80bn.

Where are Guardant Health Inc shares listed? Where are Guardant Health Inc shares listed?

Here are the trading details for Guardant Health Inc:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: GH
What kind of share is Guardant Health Inc?

Based on an overall assessment of its quality, value and momentum, Guardant Health Inc is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Guardant Health Inc share price forecast 2021?

Shares in Guardant Health Inc are currently priced at $135.39. At that level they are trading at 32.43% discount to the analyst consensus target price of 0.00.

Analysts covering Guardant Health Inc currently have a consensus Earnings Per Share (EPS) forecast of -3.612 for the next financial year.

How can I tell whether the Guardant Health Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Guardant Health Inc. Over the past six months, the relative strength of its shares against the market has been 1.28%. At the current price of $135.39, shares in Guardant Health Inc are trading at 7.39% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Guardant Health Inc PE Ratio?

We were not able to find PE ratio data for Guardant Health Inc.

Who are the key directors of Guardant Health Inc?

Guardant Health Inc's management team is headed by:

Helmy Eltoukhy - CEO
AmirAli Talasaz - CHM
Michael Wiley - OTH
Bahija Jallal - IND
Ian Clark - LED
Stanley Meresman - IND
Samir Kaul - IND
Kumud Kalia - CIO
Vijaya Gadde - DRC
Michael Bell - CFO
Craig Eagle - OTH
Who are the major shareholders of Guardant Health Inc?

Here are the top five shareholders of Guardant Health Inc based on the size of their shareholding:

The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 7.54% (7.62m shares)
SB Investment Advisers (UK) Limited Investment Advisor
Percentage owned: 5.63% (5.69m shares)
Morgan Stanley Investment Management Inc. (US) Investment Advisor/Hedge Fund
Percentage owned: 4.42% (4.47m shares)
BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 4.41% (4.46m shares)
Viking Global Investors LP Hedge Fund
Percentage owned: 3.5% (3.53m shares)
Similar to GH
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.